Hai-Yan Xu (Haiyan Xu)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 11

Top Topics

Chronic Myeloid Leukemia

Ejection Fraction

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Cancer management and research

Targeted oncology

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Xin Ai, Si-Yu Lei, Hai-Yan Xu, Yan Wang
Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study. Thoracic cancer (2023)
Si-Yu Lei, Hai-Yan Xu, Hong-Shuai Li, Ya-Ning Yang, Fei Xu, Jun-Ling Li, Zhi-Jie Wang, Pu-Yuan Xing, Xue-Zhi Hao, Yan Wang
Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thoracic cancer (2023)
Fei Xu, Heng-Chi Chen, Hai-Yan Xu, Jun-Ling Li, Xuezhi Hao, Pu-Yuan Xing, Jianming Ying, Yan Wang
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 13 (22) (2022)
Yaning Yang, Xin Ai, Hai-Yan Xu, Guangjian Yang, Lu Yang, Xuezhi Hao, Ke Yang, Yuling Mi, Guizhen Wang, Shuyang Zhang, Siyu Lei, Yan Wang
Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice. Thoracic cancer 13 (23) (2022)
Hai-Yan Xu, Weihua Li, Guangjian Yang, Junling Li, Lu Yang, Fei Xu, Yaning Yang, Jianming Ying, Yan Wang
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. Targeted oncology 15 (3) (2021)
Lu Yang, Xuezhi Hao, Xingsheng Hu, Zhijie Wang, Ke Yang, Yuling Mi, Yaning Yang, Hai-Yan Xu, Guangjian Yang, Yan Wang
Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. Thoracic cancer 11 (12) (2020)
Lu Yang, Chong Pang, Fei Xu, Guangjian Yang, Hai-Yan Xu, Chang-Li Wang, Yan Wang
Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery. Cancer management and research 12 (2020)
Hai-Yan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying, Shucai Zhang, Yan Wang
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. Cancer medicine 9 (10) (2020)
Fei Xu, Guangjian Yang, Hai-Yan Xu, Lu Yang, Weini Qiu, Yan Wang
Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. Thoracic cancer 11 (3) (2020)
Hai-Yan Xu, Guangjian Yang, Lu Yang, Yaning Yang, Di Ma, Junling Li, Xuezhi Hao, Puyuan Xing, Yan Wang
Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance. Thoracic cancer 10 (5) (2019)
Hai-Yan Xu, Fei Xu, Wenjie Zhu, Jianming Ying, Yan Wang
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. Thoracic cancer 9 (8) (2018)